University Hospitals Birmingham NHS Foundation Trust

Loading results...
View full results list

Medicines A–Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

R

Status	Drug name	NICE TAs	Comments
	Risankizumab (Skyrizi®)	TA998: Risankizumab for treating moderately to severely active ulcerative colitis
	Risdiplam (Evrysdi®)	TA755 - Risdiplam for treating spinal muscular atrophy
	Risendronate tablets
	Risperidone injection		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
	Risperidone liquid		ESCA
	Risperidone tablets		ESCA
	Ritlecitinib	TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over
	Ritumixab infusion (Mabthera®, Truxima®)	TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
	Rituximab	TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma TA193 - Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia TA174 - Rituximab for the first-line treatment of chronic lymphocytic leukaemia TA137 - Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma TA65 - Rituximab for aggressive non-Hodgkin's lymphoma TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis TA226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
	Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD

Building healthier lives